Genetic variation in immune-regulating components such as cytokines may lead to interindividual differences in immunosuppression response and susceptibility to melanoma. We evaluated the associations between genetic variants in five interleukins (IL) and IL receptor genes (IL-4, IL-4R, IL-6, IL-6R, and IL-10) and the risk of melanoma. Twenty-five single nucleotide polymorphisms (SNPs) were selected that are functionally relevant or tagging SNPs of each gene. We conducted a nested case-control study of 219 female patients and 219 matched controls within the Nurses' Health Study. We observed that in the IL-6R gene, four SNPs in linkage disequilibrium were associated with an increased risk of melanoma. Three are located in introns (rs6684439, rs4845618, and rs4845622), and one is a nonsynonymous SNP in exon 9 [rs8192284 (Asp358Ala)]. An elevated risk of melanoma was observed in the heterozygous groups of these SNPs with odds ratio of 1.74 [(95% confidence interval, 1.07, 2.81) for rs6684439, 1.72 (1.04, 2.84) for rs4845618, 1.69 (1.03, 2.75) for rs4845622, and 1.68 (1.04, 2.73) for rs8192284]. But these associations were not observed in the homozygous variant group with odds ratios ranging from 0.93 to 1.03. We did not find significant results for the SNPs in the other four genes. These data suggest the involvement of IL-6R in melanoma development. Further studies are needed to confirm these findings.
Interleukin and interleukin receptor gene polymorphisms and susceptibility to melanoma Introduction
Melanoma is the most serious form of skin cancer, and its incidence rate has been increasing in recent decades in the United States. Ultraviolet exposure is the most important risk factor for melanoma [1] .
Studies with immune-suppressed renal transplant patients suggest that immune suppression contributes to melanoma susceptibility [2] . Cytokines, secreted in response to immune stimuli, are important in mediating and regulating immune response. Interleukin (IL)-10 is an anti-inflammatory factor produced by multiple cell types such as keratinocytes. IL-10 acts as a promoter of human melanoma by inducing melanoma cell proliferation [3] and downmodulating the antitumor immune response [4, 5] . Conversely, IL-10 exerts antitumor and antimetastatic activity by inhibiting angiogenesis [6] . IL-4, secreted by CD15 + neutrophils and Th2 cells, can induce IL-10 secretion [7] . IL-6, a proinflammatory factor secreted by keratinocytes and macrophages, acts as a tumor growth inhibitor for early-stage melanomas but as a growth factor for advanced-stage tumor cells [8] . These cytokines act by binding to specific membrane receptors.
Genetic variation of these cytokines and their receptor genes may lead to different immune responses and susceptibility to melanoma. Only a few studies have, however, examined single nucleotide polymorphisms (SNPs) in these genes in relation to melanoma susceptibility, and the results are mixed. Howell et al. [9] reported that a low-expression genotype in the IL-10 promoter region is a risk factor for more advanced/poorer prognosis melanoma and may confer susceptibility to melanoma in British Caucasians (165 patients and 158 controls). No significant results were obtained for the IL-4-590 C/T and IL-6-174 G/C SNPs with regard to melanoma risk among 169 patients and 261 controls by the same group [10] . Recently, Nikolova et al. [11] found that the genotype frequency distribution of three IL-10 SNPs and one IL-6 SNP in 122 Caucasian melanoma patients were significantly different from those reported in healthy Caucasians.
We investigated the association between five cytokine/ cytokine receptor genes (IL-4, IL-4R, IL-6, IL-6R, and IL-10) and melanoma susceptibility in a nested casecontrol study of 219 incident melanoma patients and 219 matched controls within the Nurses' Health Study (NHS) cohort. We selected 25 SNPs in these genes (two in the IL-4 gene, two in the IL-4R gene, seven in the IL-6 gene, ten in the IL-6R gene, and four in the IL-10 gene) and evaluated their association with melanoma risk.
Materials and methods

Study population
The NHS was established in 1976, when 121 700 female registered nurses between the ages of 30 and 55 years, residing in 11 larger US states, completed a selfadministered questionnaire on their medical histories and baseline health-related exposures. Updated information has been obtained by questionnaire every 2 years. During 1989 and 1990, blood samples were collected from 32 826 of the cohort members. The distribution of risk factors for skin cancer in the subcohort of those who donated blood samples was similar to that in the overall cohort. Eligible patients in this study consisted of women with incident melanoma from the subcohort who had given a blood specimen, with a diagnosis any time after blood collection up to 1 June 2000, and with no earlier diagnosed skin cancer. One control per case was selected randomly from participants who gave a blood sample and were free of diagnosed skin cancer up to and including the questionnaire cycle in which the case was diagnosed. Controls were matched to patients by year of birth ( ± 1 year) and self-reported race (Caucasian/ missing). Fewer than 5% of patients and controls lacked race/ethnicity data. The nested case-control study consisted of 219 melanoma patients and 219 controls. The study protocol was approved by the Committee on Use of Human Subjects of the Brigham and Women's Hospital, Boston, Massachusetts, USA.
Exposure data
Information regarding skin cancer risk factors was obtained from the prospective biennial questionnaires and the retrospective supplementary questionnaire. Questions on natural hair color and childhood and adolescent tanning tendency were asked in the 1982 prospective questionnaire and for the ethnic group in the 1992 questionnaire. In the skin cancer nested casecontrol study, natural skin color and other sun exposurerelated information were collected by the retrospective supplementary questionnaire in 2002. In addition, the 11 states of residence of cohort members at baseline were grouped into three regions: Northeast (Connecticut, Massachusetts, Maryland, New Jersey, New York, and Pennsylvania), Northcentral (Michigan and Ohio), and West and South (California, Texas, and Florida). Estimation of past sunlight exposure for each patient was described earlier [12] .
Single nucleotide polymorphism selection
Twenty-five common SNPs (minor allele frequency greater than 5%) were selected for the five IL genes (Table 1 ). For IL-6, we included five tagging SNPs (rs2069827, rs1554606, rs2069849, rs2069861, and rs1818879) from the Seattle SNPs database (http:// pga.gs.washington.edu/) and two well-studied SNPs associated with other diseases (rs1800797 and rs1800795). Detailed information was described elsewhere [13] . For IL-6R, 10 tagging SNPs were chosen with the HapMap CEU (www.hapmap.org) population as the reference panel and an r 2 of 0.8 as the threshold using a pair-wise linkage disequilibrium tagging approach by the Tagger program (http://www.broad.mit.edu/mpg/tagger/) [14] . For genes IL-4, IL-4R, and IL-10, potential functional SNPs were chosen on the basis of published papers [15] [16] [17] . The positions of these SNPs are annotated according to the SNP500 Cancer database (http://snp500cancer.nci.nih.gov).
Laboratory assays
We performed genotyping on OpenArray SNP Genotyping System (BioTrove, Woburn, Massachusetts, USA). Laboratory personnel were blinded to case-control status, and 42 blinded quality control samples were inserted to validate genotyping procedures; concordance for the blinded samples was more than 99%. Primers, probes, and conditions for genotyping assays are available upon request. Interleukin, interleukin receptor and melanoma Gu et al. 331
Statistical analyses
We used SAS v9.0 (SAS Institute, Cary, North Carolina, USA) for all statistical analyses. PROC ALLELE was used to test whether the genotype frequency distribution for each SNP was a departure from the Hardy-Weinberg equilibrium among the controls.
As conditional and unconditional logistic regression analyses yielded similar results, to increase statistical power, we used unconditional logistic regression to evaluate the association of genotype and melanoma risk. We first did simple analyses adjusting for matching factors (age and ethnicity), and then multivariate analyses adjusting for matching factors, constitutional susceptibility score, family history of melanoma, the number of lifetime severe sunburns that blistered (0, 1-5, 6-11, or > 11), sunlamp use or tanning salon attendance (yes/ no), cumulative sun exposure while wearing a bathing suit, and geographic region. For each SNP, the odds ratio (OR) and 95% confidence interval (CI) were calculated for the heterozygous group (genotype with one common allele and one rare allele) and the homozygous variant group (genotype with two rare alleles) separately using the wild type (genotype with two common alleles) as the reference group. The P value was obtained from a 2degree of freedom test. For some SNPs with the sparse homozygous variant group (the expected number was fewer than five for either patients or controls), we combined the heterozygous and homozygous variant groups and calculated the OR and 95% CI for the combined group. The P value was obtained from a 1-degree of freedom test. Constitutional susceptibility score was a summarized multivariate confounder score using multiple skin cancer risk factors such as natural skin color, natural hair color, childhood, or adolescent tendency to burn, and the number of palpably raised moles on arms as the predictors. The detailed information for constructing the constitutional susceptibility score and the cumulative sun exposure while wearing a bathing suit was described earlier [18] .
In the evaluation of gene-environment interactions between the genetic variations and the nongenetic risk factors (cumulative sun exposure with a bathing suit, number of lifetime severe sunburns, and family history of melanoma) on melanoma susceptibility, we added one interaction term between the risk factors (coded as ordinal) and SNP variables (coded as 0, 1, 2) to the logistic regression models with main effects only. The P value of this interaction term was used to evaluate whether the effect of the SNP on melanoma susceptibility differed significantly by these risk factors.
We used several major bioinformatic tools to predict the potential functions of four SNPs in the IL-6R gene. For the SNP rs8192284 (Asp358Ala; a nonsynonymous SNP in exon 9), we used four major bioinformatic methods:
(i) BLOSUM62 [19] , (ii) PolyPhen [20] , (iii) SIFT [21] , and (iv) SNPs3D [22] . For the other three SNPs in the intron region (rs6684439, rs4845618, rs4845622), we first used SNPHunter (www.hsph.harvard.edu/ppg/software.htm) [23] to retrieve the 5 0 and 3 0 35-base pair (bp) or 300-bp (for CpG island analysis) flanking sequences for each of the three intronic SNPs. Then, we used four in-silico prediction programs, (i) NNSPLICE 0.9 version (http://www.fruitfly.org/seq_tools/splice.html) [24] , (ii) Branch-Site Analyzer (http://ast.bioinfo.tau.ac.il/BranchSite. htm), (iii) CpG Islands Searcher (www.cpgislands.com/) [25] , and (iv) TFSEARCH (http://www.cbrc.jp/research/db/ TFSEARCH.html) to predict whether each SNP could be located in donor or acceptor splice site, the branch site or the polypyrimidine tract of the intron, CpG island or transcriptional factor binding site, respectively.
Results
The mean age at diagnosis of melanoma patients was 63.4 years, the same as that of controls. Patients were more likely than controls to live in the west and south area (25.1 vs. 18.7%), to have a family history of melanoma (15.3 vs. 6.0%), and to use a sunlamp or attend a tanning salon (23.1 vs. 13.1%). Patients also had a higher constitutional susceptibility risk score, cumulative sun exposure with a bathing suit, and mean number of lifetime severe sunburns ( Table 3 ). The former three SNPs are in intron regions, and rs8192284 is a nonsynonymous SNP in exon 9. No material difference between simple and multivariate analyses was found. We illustrate the positions and the linkage disequilibrium structure of these SNPs in Fig. 1 . We did not find significant results for SNPs in the other four genes.
We found no evidence of gene-environment interactions between these five genes and melanoma risk factors (cumulative sun exposure with a bathing suit, the number of lifetime severe sunburns, and family history of melanoma) on melanoma susceptibility.
Through the functional prediction of the rs8192284 (Asp358Ala), we found a score of -2 by the BLOSUM62, indicating that the Asp358Ala is likely to be deleterious to the protein structure. The PolyPhen PSIC score difference (D) is 1.667, which is considered 'possibly damaging' as well. In contrast, the score of 0.17 by the SIFT TI (with a MSCS = 3.66) and the SVM profile score of 0.04 by the SNPs3D suggest that this SNP is possibly tolerated or not deleterious.
The three intronic SNPs, rs6684439, rs4845618, and rs4845622, are located more than 1000bp from either the 5 0 or the 3 0 boundaries of introns 1 or 6: rs6684439 is located at the 17 649-bp position in intron 1 (size = 23 481 bp), rs4845618 is located at the 21 825 bp position in intron 1 (size = 23 481bp), and rs4845622 is located at the 2833 bp position in intron 6 (size = 12014 bp). Results of NNSPLICE showed that none of the three intronic SNPs was located in donor or acceptor splice sites. Results of Branch-Site Analyzer showed that none of them was located in any branch sites or polypyrimidine tracts in their respective introns. Results of CpG Islands Searcher indicated that none of them was located in CpG islands. Results of TFSEARCH indicated that only rs6684439 is located in two putative transcriptional binding sites, GATA-1 (TRANSFAC accession number M00075) and deltaEF1 (TRANSFAC accession number M00073). Taken together, these results suggest that rs6684439 could have a functional impact on IL-6R transcriptional regulation by altering two putative transcriptional binding sites, but rs4845618 and rs4845622 are likely to be nonfunctional. Unconditional logistic regression adjusted for the matching variables [age and race (Caucasian and missing)], constitutional susceptibility score, family history of melanoma, the number of lifetime severe sunburns that blistered, sunlamp use or tanning salon attendance (yes/no), cumulative sun exposure while wearing a bathing suit, and geographic region. We estimated the odds ratios (OR) of heterozygous and homozygous variant groups separately with the wild type as the reference and the P values were obtained from 2-degree of freedom tests. For some SNPs with expected cell count in homozygous variant group of fewer than 5 for either cases or controls, we combined heterozygote and homozygous variant into one category (variant carriers), and the P values are based on 1-degree of freedom tests. The number of participants does not sum to total women because of missing data on genotype. CI, confidence interval; SNP, single nucleotide polymorphism.
Discussion
Genetic variations in cytokine genes may influence melanoma susceptibility. Only a few epidemiological studies have, however, examined the associations of IL-10 [9, 11] , IL-4 [10] , and IL-6 [10, 26] genes with melanoma risk. The IL-4R and IL-6R genes have not been earlier examined. We evaluated the association of 25 SNPs in these five genes with melanoma susceptibility in a nested case-control study of 219 patients and 219 matched controls within NHS.
IL-6 acts as a tumor growth inhibitor for early-stage melanoma and a growth factor for tumor cells of advanced stage in vitro [8] . Among metastatic malignant melanoma patients treated with biochemotherapy, those with a higher pretreatment serum IL-6 level have a shorter survival time [27] . In two epidemiological studies, no significant association was, however, observed between IL-6-174 G/C, a SNP regulating IL-6 production [28] , and melanoma susceptibility or prognosis [10, 26] . Our study assessed five tagging SNPs in this gene and two well-studied SNPs, one of which is IL-6-174 G/C (rs1800795). We found no significant association between these SNPs and melanoma risk. IL-6 exerts its biological effects by binding to IL-6R, which then signals the cell via second messengers to alter gene expression. We found that four linked SNPs in the IL-6R gene were associated with melanoma risk; the heterozygous groups had higher risk than wild types with ORs ranging from 1.68 to 1.74. This significantly increased risk was not observed for their homozygous variant groups with the lower bounds of the CIs 0.45-0.53, and the upper bounds 1.83-1.95. There are several interpretations for this observation: it is possible that the significant associations in the heterozygous groups were false-positive (because of multiple testing). Another explanation is that the null results in the homozygous variant groups may be because of the wide CI (the OR ranged from about 0.5 to 2.0). Therefore, replication of this finding in other studies is warranted. Among these four SNPs, rs8192284 (Asp358Ala) is a well-studied nonsynonymous SNP in exon 9. Prediction by two bioinformatic tools, BLOSUM62 and PolyPhen, suggests that this polymorphism could possibly damage the protein structure of IL-6R. According to an in-vitro study of human cells, Asp358Ala occurs in a major position close to the transmembrane region of the protein, and this amino acid substitution could alter the shedding of the membrane-bound IL-6R to the soluble IL-6R [29] . Substitution of the aspartate with gly at position 358 reduced the shedding by 26% [29] . In a study of 115 healthy volunteers, Galicia et al. [30] reported that ala carriers had higher serum soluble IL-6R levels. In terms of the other three SNPs in the intron regions, the SNP rs6684439 in the intron 1 was predicted to be located in two putative transcriptional factor (GATA-1 or deltaEF1) binding sites by the TFSEARCH algorithm. We cannot eliminate the possibility of false-positive observations in the heterozygous groups. Considering these potential functions of the rs8192284 and rs6684439, it is, however, worthwhile to perform replication and functional studies to determine the role of the IL-6R gene and its products in melanoma susceptibility and prognosis.
IL-10 is an important cytokine with multiple functions in terms of tumor progress. As a potent immunosuppressive cytokine, IL-10 has a potential cancer-promoting function by inhibiting the T-cell immune response against tumor cells [5] . IL-10 can also act as an autocrine growth factor for melanoma cells [3] . Conversely, the antitumor activity of IL-10 has been reported as well in the form of inhibition of angiogenesis [6] . Several case-control studies were performed for this gene with melanoma susceptibility and prognosis, and the results with susceptibility were inconsistent. Howell et al. [9] found that a low-expression genotype in the IL-10 promoter region ( -1082 AA) is a risk factor for more advanced/ poorer prognosis melanoma and may confer susceptibility to melanoma. According to Alonso et al. [31] , the SNP -1082 A/G was not associated with melanoma susceptibility but the researchers observed associations among male patients of older age at diagnosis, and with the overall survival rate in patients of advanced disease. Vuoristo [32] reported a haplotype carrier (A in -1082, . Black squares represent high linkage disequilibrium (LD), white squares represent low LD. r 2 = 0.49 between SNP4 (rs6684439) and SNP5 (rs4845618); r 2 = 0.92 between SNP4 and SNP6 (rs4845622); r 2 = 0.89 between SNP4 and SNP7 (rs8192284); r 2 = 0.46 between SNP5 and SNP6; r 2 = 0.44 between SNP5 and SNP7; r 2 = 0.89 between SNP6 and SNP7.
T in -819, and A in -592), which was associated with susceptibility to melanoma, and with longer survival in advanced melanoma patients. In this study, we did not find a significant association between four IL-10 SNPs (including the three SNPs well studied earlier) and melanoma risk. We did not have stage or other prognostic indicators, which limited our ability to evaluate the relation of the IL-10 gene with melanoma prognosis. IL-4 can induce IL-10 secretion by peripheral blood lymphocytes [7] . Howell et al. [10] did not find an association between the SNP IL-4-590 and melanoma susceptibility or prognosis. Similarly, no significant results were observed in our study for the two IL-4 SNPs and two nonsynonymous IL-4R SNPs in relation to melanoma risk.
It is worth noting that for IL-10, IL-4, and IL-4R genes, we selected SNPs according to published papers rather than a tagging SNP approach. For some cytokines, such as IL-10 and IL-6, the functions are complex and may vary in different melanoma stages. We, however, do not have enough information to do subgroup analyses.
In conclusion, the IL-6R gene may be involved in melanoma susceptibility; replication in larger samples and further functional study are warranted. Hence, when studying cytokine genes, the cytokine receptor genes may be worth investigating as well.
